Taken together, these data suggest that SHP2 inhibitors may overcome adaptive resistance to FGFR inhibitors possibly due to activation of other RTKs or other SHP2 activation mechanisms in FGFR-driven cancers. The gene discussed is PTPN11; the disease is cancer.